Skip to main content
NIH Clinical Center
  Home | Contact Us | Site Map | Search
About the Clinical Center
For Researchers and Physicians
Participate in Clinical Studies

This file is provided for reference purposes only. It was current when it was produced, but it is no longer maintained and may now be out of date. Persons with disabilities having difficulty accessing information may contact us for assistance. For reliable, current information on this and other health topics, we recommend consulting the NIH Clinical Center at
Clinical Center News

Published monthly for CC employees by Office of Communications, Patient Recruitment, and Public Liaison.

past issues

October 2011 Special Edition

Clinical Center awarded Lasker~Bloomberg Award for public service

In your words: what is it about the Clinical Center?

CC community celebrates receipt of Lasker~Bloomberg Award

Note from the Clinical Center Director

CC Lasker Award nomination

Accomplishments at America's clinical research hospital

Clinical Center historical timeline: highlights through history

Clinical Center news briefs

Upcoming Lectures

New Clinical Research Protocols


Clinical Center awarded Lasker~Bloomberg Award for public service

Dr. Gallin accepting Lasker~Bloomberg Award

Dr. John I. Gallin, CC director (second, from left) accepted the 2011 Lasker~Bloomberg award on behalf of the CC and the NIH from (from left) Maria Freire, Lasker Foundation president; Michael Bloomberg, New York City Mayor and the award’s namesake; Alfred Sommer, Lasker Foundation chair; and Dr. Harvey Fineberg, president of the Institute of Medicine and chair of the 2011 Lasker Foundation Public Service Award Committee.

In September the Clinical Center was named the 2011 recipient of the Lasker~Bloomberg Public Service Award from the Albert and Mary Lasker Foundation, an organization that has recognized outstanding advances in medical research each year since 1945.

Dr. John I. Gallin, CC director, accepted the award on behalf of the CC and the NIH at the recognition ceremony hosted by the Lasker Foundation in New York City on September 23. The award honors the CC for serving as a model institution that has transformed scientific advances into innovative therapies and provided high-quality care to patients.

Lasker Award recipients

With Dr. John I. Gallin, CC director (left) are the 2011 Lasker Award recipients including (from left) Dr. Tu Youyou, a scientist at China Academy of Chinese Medical Sciences in Beijing who discovered artemisinin and its utility for treating malaria; Dr. Arthur L. Horwich of Yale University School of Medicine and Dr. Franz-Ulrich Hartl, of the Max Planck Institute of Biochemistry in Germany, who were honored for their discoveries concerning the cell's protein-folding machinery.

The award description recognizes the CC for spearheading major advances in a wide array of medical arenas, establishing an example for academic institutions across the country, and training thousands of investigators, many of whom now lead academic and research institutions across the world.

The award also acknowledges the CC and the NIH's rich history of medical discovery through clinical research since the hospital opened in 1953. Since then, nearly half a million volunteers have participated in clinical research at the CC and its mission has remained consistent—providing exceptional clinical care for research volunteers, an environment for innovative bedside-to-bench clinical research, and training for clinical researchers.

"The Clinical Center, the world's largest clinical research hospital, exists to help scientists who are clinicians rapidly translate promising discoveries in the laboratory into new and better ways to treat and prevent disease," said NIH Director Dr. Francis S. Collins. "The Clinical Center's 58-year research portfolio has resulted in remarkable medical advances."

Those medical milestones include development of chemotherapy for cancer;

Jerry Sachs and Mandy Young

Patients Jerry Sachs and Mandy Young represented the CC's partners in research at the September 23 Lasker Award ceremony.

the first use of an immunotoxin to treat a malignancy; identification of the genes that cause kidney cancer, leading to the development of six new, targeted treatments for advanced kidney cancer; the demonstration that lithium helps depression; the first gene therapy; the first treatment of AIDS (with AZT); and the development of tests to detect AIDS/HIV and hepatitis viruses in blood, which led to a safer blood supply.

"The Clinical Center's work has always depended on patients and healthy individuals from around the world who volunteer for clinical research here," said Gallin. "Our patients include those with rare diseases, common disorders, and undiagnosed conditions ... and the patients and healthy volunteers who participate in them are true partners in research."

The Lasker~Bloomberg Public Service Award also recognizes the CC for excelling in training the next generation of clinical researchers. Advancements through clinical research also depend on having a cadre of investigators trained to do it, Gallin added. "Students in the health sciences and clinicians come here to learn how to conduct clinical research by working closely with NIH investigators. Since 1995, more than 22,000 students around the world have participated in the CC's clinical research training curriculum offered through distance-learning programs."

Back to Top


In your words: what is it about the Clinical Center?

“There is no place like the Clinical Center because of the staff that work here and the love that they have for what they are doing.”
- Michael Kenny, Clinical Center patient

Michael Kenny
Beena Mathew

“The research that we do here matters. As new diseases are discovered, we need more understanding of how we can treat and help people.”
- Beena Mathew, Clinical Center pharmacist

There's a current in the air of the Clinical Center—a feeling of excitement, compassion, and hope among the clinician-scientists making discoveries at the lab bench, the nurses providing world-class care, and the patients trying a new therapy and contributing to biomedical research. That current is the result of the unique and special qualities of this House of Hope. CCNews asked some of those clinician-scientists, nurses, and patients to articulate that feeling and explain why the CC is so special and unique.

Ellen Berty, patient: "When I am here I feel like I am a valuable member of a team and I am helping my doctors figure things out. I'm not just the patient; I feel like my doctors and I are on a team together."

Dr. Anthony S. Fauci, director, NIAID: "The CC is a national treasure and a unique resource; its bedside-to-bench approach has helped transform many disciplines, including the study of the pathogenesis of HIV/AIDS, the development of therapies for HIV disease, as well as the study of a host of autoimmune and auto-inflammatory diseases."

Migdalia Goba, senior nursing consultant, CC: "I really enjoy the chance to meet people from all over the world, the wealth of knowledge, the opportunities for inquiry, and just being able to conduct research. All that is under one roof, which I think is really cool."

Dr. John Haughton, patient: "The most cutting-edge protocols, combined with immediate access to key tests, sometimes tests and treatment not available elsewhere—administered by truly compassionate personnel, led by an administrative team with the patient and their clinical care at the center of their focus—make the Clinical Center a unique place to be seen as a patient."

Michael Kenny, patient: "There is no place like the Clinical Center because of the staff that work here and the love that they have for what they are doing."

Chad Koratich, nursing consultant, CC: "The nurses and clinicians and other staff who work here are some of the most energized, excited, compassionate people that I have ever worked with, and I think when you combine that spirit of the people working here with the spirit of the patients, it just creates this atmosphere of hope like no place I have ever felt before."

Dr. Marston Linehan, chief, Urologic Oncology Branch, NCI: "These remarkable people, in this remarkable Clinical Center, give both help and hope to many patients affected with both rare and common disorders. It is an honor to have the opportunity to work, for the past 29 years, with such a committed group of individuals."

Beena Mathew, pharmacist, CC: "The research that we do here matters. As new diseases are discovered, we need more understanding of how we can treat and help people."

Dr. Lynnette Nieman, senior investigator, NICHD: "Clinical investigators' ability to develop new diagnostic tests and to expand knowledge of normal physiology is aided greatly by the Clinical Center's nurses' expertise, recruitment by the patient recruitment office, and investigational new drug administration by the Pharmaceutical Development Section."

Dr. Griffin Rodgers, director, NIDDK: "By enabling some of the world's top medical researchers to collaborate in innovative, interdisciplinary ways, the CC has been pivotal in advancing clinical studies that are at the forefront of solving the nation's most pressing public health issues—all while providing respect, empathy, and attention to detail in every aspect of care for the patient volunteers."

Jerry Sachs, patient: "They're really right at the latest and greatest of theories and practices available anywhere in the world, and you are part of the process. They care about you as an individual. It is a wonderful, warm atmosphere here."

Mandy Young, patient: "If you can't get hope here, you're not going to get it anywhere. We have the brightest minds, the best scientists, the best doctors, the most advanced medicine and technology. You can't not be hopeful here."

Back to Top


CC community celebrates receipt of Lasker~Bloomberg Award

Unveiling of the Lasker~Bloomberg Award

CC patient Ellen Berty; Dr. Michael Gottesman (center), NIH deputy director of intramural research; and Dr. John I. Gallin, CC director, unveiled the 2011 Lasker~Bloomberg Award at the September 28 celebration.

Music, applause, cheer, and people filled the atrium on September 28 when patients, staff, and other members of the Clinical Center community gathered to celebrate receipt of the 2011 Lasker~Bloomberg Award for Public Service.

"Each of you should be bursting with pride," said Dr. John I. Gallin, CC director, who accepted the award on behalf of CC research volunteers and NIH intramural staff, researchers, and clinicians at a ceremony hosted by the Albert and Mary Lasker Foundation in New York City on September 23. "The Lasker~Bloomberg Public Service Award is the highest such honor given in this country. In the past it has usually been given to recognize an individual, but this year the foundation made the enlightened decision to recognize the work done here at the Clinical Center since its opening in 1953," he said.

Gallin introduced patient representative Ellen Berty, who underwent a pancreatic islet cell transplant at the CC in 2001, which dramatically improved her diabetes. Berty described how honored she felt to be a part of the CC team both as a representative of CC patients and as a member of the patient advisory group. "This team that I am a part of is always striving toward a common worthwhile goal—answering questions about health, and they have done an outstanding job."

Gallin also noted that the Lasker~Bloomberg Award carries with it an honorarium of $250,000 and invited members of the NIH community to email him with ideas for its use.

Dr. Collins with guitar

Dr. Francis S. Collins, NIH director, serenaded the crowd at the Lasker Award celebration.

Lasker~Bloomberg Award statue

The award is a replica of the famous “Winged Victory of Samothrace,” also called “Nike of Samothrace,” sculpture created by the Greeks.

Dr. Michael Gottesman, NIH deputy director for intramural research, commended the CC for being a key element in the NIH's intramural research program. "The CC's mission has remained steady over the decades—providing exceptional care for patients who come here, maintaining a supportive and responsive environment for the conduct of clinical research, and training clinical investigators of the future."

Gottesman also noted that the Lasker Foundation has bestowed awards on many of the talented clinician-investigators who trained or worked at the CC, describing their profound contribution to health and medicine. "I think there is no other institution that has made a greater impact on the health of this country," he said.

NIH Director Dr. Francis S. Collins helped Gallin, Gottesman, and Berty unveil the award, describing compelling emails from CC patients talking about their experience and wonderful care they received at the CC. "Their recognition of the special, personal attention that they receive from every member of the staff makes this not only a great place for intellectual exploration," he said, "but it also makes this a place of great humanity."

Collins described the impact the CC has had upon modern medicine and reflected upon some of the medical advances that were cited in the Lasker Award nomination. He also praised and recognized everyone in the audience for their role in the award. "It's not the building we are celebrating," he said. "It's the people, people who have put in years and years of work here to accomplish so many things that have changed the face of medicine."
Collins picked up his guitar and gave a special musical performance to honor the CC community's contribution, inviting the crowd to join him as he sang a song for "all of the good people" at the CC.

This is a song for the Clinical Center
A vision and mentor
where new dreams arise
We seek here new answers
for infections and cancers
And now these advances
bring a Lasker prize

The award—a replica of the "Winged Victory of Samothrace," also called "Nike of Samothrace," sculpture created by the Greeks in 190 BC to honor the goddess of victory—was chosen by Mary Lasker because it represented in her words, "victory over disability, disease, and death." The CC's award will be placed on permanent display on the first floor to the east of the South elevators, across from the wall honoring the NIH Lasker awardees.

Back to Top


Note from the Clinical Center Director

Dr. John I. Gallin

Dr. John I. Gallin accepted the Lasker~Bloomberg Public Service Award on September 23.

Editor's note: Dr. John I. Gallin, Clinical Center director, accepted the 2011 Lasker-Bloomberg Public Service Award on behalf of the NIH and the CC. These are his remarks from the ceremony on September 23.

"What a wonderful gift Congress gave to the American public, and to the world, when it created the Clinical Center at NIH in 1947, a hospital literally wrapped in research laboratories to enable clinical research studies.

"The Clinical Center, situated less than 10 miles from the heart of our nation's capital, is very much a living monument to our country's sustained commitment to clinical research. It is a place where the bedside-to-bench cycle, which translates basic science discoveries into new treatments and cures to improve public health, is a part of everyday life.

"Of all the people who comprise the NIH Clinical Center community and the national clinical research enterprise, the contribution of the patients and healthy volunteers is critical. Their partnership makes clinical research possible—they enable a hopeful future of discovery in medicine. It is for this reason that I am delighted that two Clinical Center patients are with us today: Mr. Jerry Sachs, a dedicated member of the Clinical Center's Patient Advisory Group and a two-time cancer survivor, and Ms. Mandy Young, a patient of mine who was the first patient identified with a rare disease known as IRAK-4 deficiency. Jerry and Mandy represent the nearly 500,000 patients who have been seen at the Clinical Center since it first opened in 1953 and who are now studied in the magnificent Mark O. Hatfield Clinical Research Center.

"Clinical research is risky business yet human subject volunteers knowingly participate. On the one hand, clinical research promises hope and help while, on the other, it involves risk. We need to study and understand better the sensitivities of patient volunteers because it is becoming increasingly difficult to recruit them to participate in our studies.
"We, at the Clinical Center, are firmly committed to assuring the vitality of the human subject volunteer population and it is for this purpose, as well as for training young clinical investigators, that we will dedicate the generous honorarium that accompanies the Lasker Award.

"I am honored and humbled to accept the 2011 Lasker~Bloomberg Public Health Service Award on behalf of the tens of thousands of public health servants and the nearly half million patient volunteers who have partnered for nearly sixty years to make the Clinical Center such a special place."

Dr. John I. Gallin, CC director

Visit the 2011 Lasker~Bloomberg Award online press room for complete remarks, award descriptions, and visual resources including a photo gallery and videos featuring the award and the Clinical Center's celebration.

Back to Top


CC Lasker Award nomination

Editor's note: Dr. Harvey Fineberg, Institute of Medicine president, chaired the 2011 Foundation's Public Service Award Committee. This is an excerpt of the speech he gave in presenting the award at the ceremony on September 23.

"The 2011 Public Service Award goes not to an individual, but to an institution, and not for a single discovery, but for sustained and singular contributions to health. Establishment of the Clinical Center at the NIH in 1953 was a far-sighted investment by the United States Government: it created a model for the fully engaged, research-intensive, academic medical center, and the NIH Clinical Center went on to train some of the country's most esteemed medical scientists.

"The Clinical Center of the NIH has provided decades of public service through a skillful marriage of science and clinical care. The center and the individuals associated with it—as investigators, care givers, and trainees—have made major progress in every area recognized by the Lasker Awards: in diagnosis, treatment, cure, and prevention of human disease.

"Beyond its success in clinical research, the NIH Clinical Center from the start has served an educational purpose, attracting talented, young researchers to train with eminent scientists and physicians. The Clinical Center boasts a stellar roster of alumni who, as trainees, played pivotal roles in the work of the center and went on to become distinguished scientific leaders throughout the United States and around the world. The impact of the center on clinical and basic science has amplified across generations and geography. "

Dr. Harvey Fineberg, 2011 Public Service Award committee chair

Back to Top


Accomplishments at America's clinical research hospital

As America's clinical research hospital, the NIH Clinical Center has provided the venue for nearly six decades of prominent ground-breaking translational research. The scientific accomplishments of investigators at the CC have led to medical breakthroughs that cover a spectrum of human disease, with innumerable contributions to medicine, health, and science.

Some select accomplishments of intramural investigators working at the CC include:

  • The development of combination chemotherapy regimens and immunotherapy for cancer [1-4]

  • The first use of an immunotoxin to treat a malignancy in the case of hairy cell leukemia [5]

  • Identification of the genes that cause kidney cancer, a discovery which provided the foundation for the development of six novel, targeted therapies approved by the Food and Drug Administration for treatment of patients with advanced kidney cancer [6, 7]

  • Treatment for cancer and other disorders induced by infection with human T-cell lymphotrophic virus [8]

  • Refinements of blood cell gradient density separation and the first platelet and granulocyte transfusions in humans [9-13]

  • The first description of a receptor critical for cell signaling [14, 15]

  • Development of tests to detect AIDS/HIV and hepatitis virus leading to significantly enhanced blood transfusion safety [16, 17]

  • Identification of the pathogenesis and the first treatment of AIDS/HIV [18, 19]

  • The use of immunosuppressive therapies for nonmalignant diseases [20-22]

  • Molecular characterization of interlukin-1, the key molecule causing fever and a vital regulator of immunology [23-25]

  • The discovery and treatment of autoinflammatory diseases [26,27]

  • Characterization of the IgE receptor [28, 29]

  • Genetic characterization of two of the four forms of chronic granulomatous diseases and the description of a key biomarker [NADPH oxidase] as a predictor of survival [30-32]

  • The first successful human artificial mitral valve replacement [33]

  • The potential utility of cardiac magnetic resonance imaging in patients with acute coronary syndrome was evaluated by CC intramural researchers [34]

  • The first clinical trial demonstrating the use of lithium for bipolar disorders [35]

  • The successful treatments of childhood obsessive-compulsive disorders and childhood schizophrenia [36, 37]

  • Demonstration that positron emission tomography [PET] scans can identify brain abnormalities in schizophrenia [38]

  • Administration of the first lymphocyte gene therapy for an inherited enzyme deficiency [Gaucher disease] [40-41]

  • Development and enhancements of technologies for virtual bronchoscopy and colonoscopy [42, 43]

  • Identification of genes that may be the source of stuttering [44]

  • The creation of one of the first electronic medical information systems for medical records, the first of which to support clinical research [45, 46]

The CC has also recognized the important role of its patients as partners in discovery, and has devoted expertise and resources to studying the safe and ethical treatment of patients in the research process. At the very first meeting of the CC's Medical Board in 1952, the board developed policy for the safety of subjects participating in clinical research that lead to the United States Policy on human subject protection [47].

Training the next generation

In addition to and in support of continued scientific accomplishments, the CC has also taken a leadership role by training current and former national leaders in clinical and translational science. Many intramural scientists, trained at the CC are now in academic leadership, members of the top medical societies, and have had their research recognized by prestigious awards. This list of CC alumni includes six Physiology or medicine Nobel laureates and 11 of 133 (8%) deans of accredited United States medical schools. In addition there have been 29 Lasker Award recipients at the NIH, mostly for clinical research conducted at the Clinical Center.


1. Frei E 3rd, Holland JF, Schneiderman M et al: A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13:1126-1148, 1958.

2. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-95,1970.

3. Li MC, Hertz R, Spencer DB: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol med 93:361, 1956.

4. Rosenberg SA, Lotze MT, Muul LM et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-92, 1985.

5. Kreitman RJ, Wilson WH, Bergeron K et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistent hairy-cell leukemia. N Engl J Med 345:241-7, 2001.

6. Linehan WM, Zbar B: Focus on kidney cancer. Cancer Cell 6:223-8, 2004.

7. Hasumi Y, Baba M, Ajima R et al: Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci 106:18722-2, 2009.

8. Waldmann TA, White JD, Goldman CK et al: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82:1701-12, 1993.

9. Freireich EJ, Judson G, Levin RH: Separation and collection of leukocytes. Cancer Res 25: 1516-20, 1965.

10. Yankee RA, Freireich EJ, Carbone PP et al: Replacement therapy using normal and chronic myelogenous leukemia leukocytes. Blood 24: 844-5, 1964.

11. Klinman A, Gaydos LA, Schroeder LR et al: Repeated plasmapheresis of blood donors as a source of platelets. Blood 18:303-9, 1961.

12. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905-9, 1962.

13. Yankee RA, Grumet FC Rogentine, GN: Platelet transfusion therapy: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 281:1208-12, 1969.

14. Gavin JR 3rd, Roth J, Jen P et al: Insulin receptors in human circulating cells and fibroblasts. Proc Natl Acad Sci 69:747-51, 1972.

15. Gavin JR 3rd, Buell DN, Roth J: Water-soluble insulin receptors from human lymphocytes. Science 178:168-9, 1972.

16. Lander JJ, Alter HJ, Purcell RH: Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J immune 106:1166-71, 1971.

17. Weiss SH, Goedert JJ, Sarngadharan MG et al: Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA 253:221-5, 1985.

18. Bowen DL, Lane HC, Fauci AS: Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med 103:704-9, 1985.

19. Yarchoan R, Klecker RW, Weinhold KJ et al: Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 8481:575-80, 1986.

20. Fauci AS, Katz P, Haynes BF et al: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:234-8, 1979.

21. Fauci AS, Haynes BF, Katz P et al: Wegener's granulomastosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76-85, 1983.

22. Boumpas DT, Barex S, Kippel JH et al: Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 112:674-7, 1990.

23. Dinarello CA, Goldin NP, Wolff SM: Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med 139:1369-81, 1974.

24. Dinarello CA, Renfer L, Wolff SM: Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 74:4624-27, 1977.

25. Dinarello CA: IL-1: discoveries, controversies and future directons. E J Immunol 40:599-606, 2010.

26. Goldbach-Mansky R, Dailey NJ, Canna SW et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-92, 2006.

27. Aksentijevich I, Masters SL, Ferguson PJ et al: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426-37. 2009.

28. Mendoza G, Metzger H: Distribution and valency of receptor for IgE on rodent mast cells and related tumour cells. Nature 264:548-50, 1976.

29. Metzger H, Rivnay B, Henkart M et al: Analysis of the structure and function of the receptor for immunoglobulin E. Mol Immunol 21:1167-73, 1984.

30. Lomax K J, Leto T L, Nunoi H et al: Recombinant 47-kD cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 245:209-12, 1989.

31. Leto, T.L., Lomax, K. J., Volpp, B. et al: Cloning of a 67K neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science. 248:727-730, 1990.

32. Kuhns DB, Alvord WG, Heller T et al: Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 363:2600-10, 2010.

33. Braunwald NS, Cooper T, Morrow AG: Complete replacement of the mitral valve: successful clinical application of a flexible polyurethane prosthesis. J THorac Cardiovasc Surg 40:1-11, 1960.

34. Kwong RY, Schussheim AE, Rekharj S et al: Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 107-531-7, 2003.

35. Goodwin FK, Murphy DL, Bunney WE Jr: Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Phychiatry 21:486-96, 1969.

36. Flament MF, Rapoport JL, Berg CJ et al: Clomipramine treatment of childhood obsessive- compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42:977-83, 1985.

37. Frazier JA, Gordon CT, McKenna K et al: An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. J Am Acad Child Adolesc Phychiatry 33:658-63, 1994.

38. Weinberger DR, Berman KF, Zec RF: Physiologic dysfunction of dorsolateral prefrontal cortex in schitzophrenia. I. Regional cerebral blood flow evidence. Arch Gen Phychiatry 43:114-24, 1986.

39. Culver KW, Osborne WR, Miller AD et al: Correction of ADA deficiency in human T Lymphocytes using retroviral-mediated gene transfer. Transfer Proc 23:170-1, 1991.

40. Barton NW, Furbish FS, Murray GJ et al: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci 87:1913-6, 1990.

41. Barton NW, Brady RO, Dambrosia JM et al: Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464-70, 1991.

42. Summers RM, Feng DH, Holland SM et al: Virtual bronchoscopy: segmentation method for real time display. Radiology 200:857-62, 1996.

43. Summers RM, Yao J, Pickhardt PJ et al: Computed tomographic virtual colonoscopy computer aided polyp detection in a screening population. Gastroenterology 129:1832-44, 2005.

44. Kang C, Riazuddin S, Mundorff J et al: Mutations in the lysosomal enzyme-targeting pathway and persistent stuttering. N Engl J Med 362:677-85, 2010.

45. Lewis TL, Macks GC: Computer applications in medical care and clinical research: a physician's perspective. Comput Hosp 1:12-23, 1980.

46. Foy JL, Palestine AG, Nealon RC et al: Adapting a hospital information system to data collection for clinical research. Proc 9th Ann Symp Comput Appl Med Care, Inst Electrical Electronics Engineers Comput Soc: 864-51, 1985.

47. McCarthy C. "The Origins and Policis that Govern Institutional Review Boards", Chapter 50 pp 542-544. In Emanuel EJ, Grady C, Crouch RA et al. Eds. Oxford University Textbook on Clinical Research Ethics. Oxford University Press. 2008. [disclaimer]


Back to Top


Clinical Center historical timeline: highlights through history

Since admitting its first patient in 1953, the Clinical Center has been a monument to clinical research and the work done to achieve better human health and discover tomorrow's cures. In the past 60 years, the CC has grown in scientific presence and physical size yet the mission to generate new ways to diagnose, treat, and prevent disease by connecting bedside observations with laboratory findings has remained.

Original CC building

The Clinical Center was designed to encourage interactions between basic scientists and clinicians. The original building had laboratories literally wrapped around patient-care units.

Surgery in process

In the 1950s and early 1960s, many operations at the CC involved cancer, cardiac, and neurosurgical procedures.

Two nurses attend to patient in ICU

Clinical research nurses have always been an important part of the CC's team. Pictured above two nurses care for a patient in the intensive care unit in the early 1960s.

June 22, 1951 - The cornerstone ceremony was officiated by Oscar R. Ewing, federal security administrator. President Harry S. Truman was the honored guest.

July 6, 1953 - The first patient was admitted to the Clinical Center.

October 22, 1981 - The ambulatory care research facility was dedicated. The research hospital was renamed the Warren Grant Magnuson Clinical Center.

March 22, 1984 - The first magnetic resonance imaging unit became operational for patient imaging.

September 14, 1990 - A 4-year-old patient with adenosine deaminate deficiency was the first to receive gene therapy treatment.

February 1996 - Details on clinical research studies conducted at the Clinical Center were made available on the internet (

July 1997 - To meet increasing investigative needs for cell products used in immunotherapy, gene therapy, and stem cell transplantation, a cell processing facility was created.

November 4, 1997 - Vice President Al Gore and Senator Mark O. Hatfield attended groundbreaking ceremonies for the Mark O. Hatfield Clinical Research Center.

July 31, 2004 - The Clinical Research Information System (CRIS), designed to replace the current Medical Information System, was launched.

April 2, 2005 - Current CC patients moved to the new Mark O. Hatfield Clinical Research Center. The hospital was dedicated on September 22, 2004.

May 2007 - The Clinical Center enrolled its first patient in the human genome sequencing study—the first of 1,000 participants to enroll in a study led by NHGRI to test the use of human genome sequencing in a clinical research setting. The study used DNA sequencing to learn whether tiny changes in selected genes indicate predisposition to or onset of common diseases.

June 2007 - State-of-the art metabolic clinical research unit opened, enabling researchers from across NIH to study factors that contribute to obesity and associated diseases.

May 2008 - The Undiagnosed Diseases Program was launched, bringing patients to the Clinical Center who seek renewed hope for puzzling, often devastating, health conditions.

July 2009 - The Biomedical Translational Research Information System (BTRIS) was activated. The launch of the NIH-wide research data repository allows principal investigators with active protocols to view their patients' identified data.

January 2010 - State-of-the-art pharmaceutical development facility opened to formulate candidate drugs.

April 2010 - Seven-bed Special Clinical Studies Unit opened with advanced isolation and extended-stay capabilities.




Back to Top


News Briefs

NIH Research Festival

Mark your calendar for this year's NIH Research Festival which will be October 24-28 in Masur Auditorium and Natcher Conference Center.

This year's festival will include scientific symposia, poster sessions, a special session on improving workplace dynamics,and the scientific equipment tent show. Meet colleagues from across campus, learn about new research efforts, and celebrate the intramural community.

For more information, visit or email

Summit on Cell Therapy for Cancer

The Summit on Cell Therapy for Cancer will be held November 1-2 in Masur Auditorium. The summit will include dynamic discussions and lectures by leaders in the field to provide an in-depth review of cell therapy as a cancer immunotherapy.

The summit will include a dynamic mix of perspectives, concepts, and techniques related to cellular therapy and will feature keynote addresses by Dr. Mahendra Rao, NIH Center for Regenerative Medicine; and Dr. Steven Rosenberg, Tumor Immunology Section chief at the National Cancer Institute.

The Summit on Cell Therapy for Cancer is presented in collaboration with the CC Department of Transfusion Medicine, the American Association of Blood Banks, the American Society for Blood and Marrow Transplantation, the American Society of Gene & Cell Therapy, and the Cancer Immunotherapy Trials Network.

For more information, visit [disclaimer].

Family Caregiver Day

Family Caregiver Day logoIn recognition of National Family Caregiver Month, the Clinical Center will host Family Caregiver Day on November 8.

The event will feature a caregiver information fair and expo from 10 am-2 pm on the seventh floor of the Hatfield building where CC departments and outside exhibitors will offer information and other resources for family caregivers.

Dr. Gary Epstein-Lubow will present the keynote from 8-9 am in Lipsett Amphitheater. Epstein-Lubow is an assistant professor in the Department of Psychiatry and Human Behavior at the Alpert Medical School of Brown University and assistant unit chief at Butler Hospital's inpatient geriatric psychiatry unit in Providence, RI. His presentation will focus on family caregiving issues including caregiver health, identifying at-risk caregivers, proven beneficial interventions, and future research.

This event does not require registration. For more program details or information on this event, visit or contact Dr. Margaret Bevans or LCDR Leslie Wehrlen at 301-402-9383 or 301-451-4077.

Back to Top


Upcoming Lectures: Grand Rounds

Lipsett Amphitheater, 12 noon- 1pm
Lectures will be videocast at

October 5, 2011
Ethics Rounds The Current Proposal to Amend the Federal Human Subjects Research Regulations: Is It a Good Idea?
Greg Koski, MD, PhD
Associate Professor of Anesthesia Senior Scientist, James Mongan Institute for Health Policy, Massachusetts General Hospital, Harvard Medical School
Former Director, Office of Human Research Protections, Department of Health and Human Services

Case Presenter:
Michelle Feige, MSW
Public Health Analyst, Office for Human Research Protections Department of Health and Human Services 

October 12, 2011 - Moved to Masur Auditorium 
Contemporary Clinical Medicine: Great Teachers Heart Matters: Old Ideas in New Times for the Patient-Doctor Relationship Katharine Kennedy Treadway, MD
Gerald S. Foster Academy Associate Professor of Medicine, Harvard Medical School 

October 19, 2011 
John Doppman Memorial Lecture for Imaging Sciences MR Elastography: A New Quantitative Imaging Biomarker
Richard L. Ehman, MD
Consultant, Department of Radiology, Mayo Clinic
Professor of Radiology, College of Medicine, Mayo Clinic

October 26, 2011 - NO GRAND ROUNDS NIH Research Festival

For more information, visit

Back to Top


New clinical research protocols

The following new clinical research protocols were approved in July:

Characteristics and Mechanism of Childhood-Onset Hemidystonia; 11-CC-0246; Dr. Diane L. Damiano; CC

Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease; 11-C-0233; Dr. Thomas S. Uldrick Jr; NCI

Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition; 11-C-0242; Dr. William D. Figg; NCI

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies; 11-C-0220; Dr. Robert Yarchoan; NCI

A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination with mTOR Inhibitor RAD001 (Everolimus) in Patients with Relapsed Multiple Myeloma or Lymphoma; 11-C-0232; Dr. Carl O. Landgren; NCI

A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered with or without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men with Advanced Castrate-Resistant Prostate Cancer; 11-C-0231; Dr. Samir N. Khleif; NCI

A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients with Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers with Hepatic; 11-C-0240; Dr. Itzhak Avital; NCI

Generation of Induced Pluripotent Stem (iPS) Cell Lines from Somatic Cells of Best Disease, Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) Patients; 11-EI-0245; Dr. Brian P. Brooks; NEI

A Pilot Phase I/II Study for the Evaluation of Dextromethorphan as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema (MiDME2); 11-EI-0244; Dr. Catherine A. Cukras; NEI

Characterization of Nutritional Status and Immune Function in Urea Cycle Disorders and Related Disorders; 11-HG-0217; Dr. Peter J. McGuire; NHGRI

Weight Management Interactions in a Virtual Clinical Environment; 11-HG-0238; Dr. Susan Persky; NHGRI

Studies on the Natural History and Pathogenesis of Spondyloarthritis; 11-AR-0223; Dr. Robert A. Colbert; NIAMS

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes; 11-CH-0239; Dr. Jack A. Yanovski; NICHD

Back to Top

This page last updated on 12/20/2017

Archived Spiderweb The information on this page is archived and provided for reference purposes only.

National Institutes
of Health
  Department of Health
and Human Services
NIH Clinical Center